CLOXAZOLAM

Details

Stereochemistry	RACEMIC
Molecular Formula	C17H14Cl2N2O2
Molecular Weight	349.211
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ClC1=CC2=C(NC(=O)CN3CCOC23C4=C(Cl)C=CC=C4)C=C1

InChI

InChIKey=ZIXNZOBDFKSQTC-UHFFFAOYSA-N

InChI=1S/C17H14Cl2N2O2/c18-11-5-6-15-13(9-11)17(12-3-1-2-4-14(12)19)21(7-8-23-17)10-16(22)20-15/h1-6,9H,7-8,10H2,(H,20,22)

HIDE SMILES / InChI

Molecular Formula	C17H14Cl2N2O2
Molecular Weight	349.211
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.sandoz.com.br/cs/www.sandoz.com.br/produtos/genericos/PS-Cloxazolam.pdf

Cloxazolam is an agonist of GABA-A receptor that was developed in Japan for the treatment of anxiety-disorders. The drug was marketed in Europe under the names Sepazon, Olcadil, Akton and Lubalix.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
GABA-A receptor; benzodiazepine site 38 Target ID: CHEMBL2109243 Sources: http://www.sandoz.com.br/cs/www.sandoz.com.br/produtos/genericos/PS-Cloxazolam.pdf	Agonist 2678

Conditions

Condition	Modality	Targets	Highest Phase	Product
Anxiety 267 Sources: https://portal.novartis.com.br/UPLOAD/ImgConteudos/1514.pdf	Primary		Approved 8429	OLCADIL Approved Use Emotional disorders such as anxiety, tension, restlessness; sleep disorders such as difficulty falling asleep, insomnia and early awakening; pre-medication prior to surgery. Launch Date 2013
Sleep disorder 20 Sources: https://portal.novartis.com.br/UPLOAD/ImgConteudos/1514.pdf	Primary		Approved 8429	OLCADIL Approved Use Emotional disorders such as anxiety, tension, restlessness; sleep disorders such as difficulty falling asleep, insomnia and early awakening; pre-medication prior to surgery. Launch Date 2013

PubMed

Title	Date	PubMed
[A case of amoxapine-induced tardive dystonia successfully treated with a low dose anti-cholinergic agent].	2000 Apr	10967655
Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone.	2003 Feb 1	12604236

Patents

Sample Use Guides

In Vivo Use Guide

Symptoms of mild to moderate severity: a tablet (2 mg) and a half to three tablets per day, divided into two administrations; Symptoms of moderately severe to severe: 3 to 4 tablets per day divided in two administrations.The optimal therapeutic dosage should be determined individually by progressive adjustment. max recommended dose: 6 tablets (12 mg)/day.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:01:44 GMT 2023` Edited by `admin` on `Fri Dec 15 16:01:44 GMT 2023`
Record UNII	GYL649Z0HY
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CLOXAZOLAM

Official Name

English

cloxazolam [INN]

Common Name

English

CLOXAZOLAM [JAN]

Common Name

English

CLOXAZOLAM [MART.]

Common Name

English

CLOXAZOLAM [MI]

Common Name

English

10-CHLORO-11B-(O-CHLOROPHENYL)-2,3,7,11B-TETRAHYDRO-OXAZOLO(3,2-D) (1,4)BENZODIAZEPIN-6(5H)-ONE

Common Name

English

Cloxazolam [WHO-DD]

Common Name

English

SEPAZON

Brand Name

English

Classification Tree Code System Code

DEA NO.

2753